Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals. Wikipedia